# Biogen (BIIB) Financial Model Free Excel 3-statement financial model and company analysis for Biogen. - Canonical: https://finamodel.com/companies/biogen - Industry: Pharmaceuticals - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/BIIB.xlsx ## Model Purpose This model evaluates whether Biogen's rapidly scaling "growth products" (Leqembi, Skyclarys, Zurzuvae) can generate sufficient cash flow to offset the structural decline of its legacy multiple sclerosis franchise, ultimately driving an equity valuation and assessing the company's capacity for further pipeline-expanding acquisitions. ## Company Overview Biogen Inc. is a leading global biotechnology company focused on discovering, developing, and delivering therapies for neurological, immunological, and rare diseases. The company is currently undergoing a massive strategic pivot, transitioning away from its historical reliance on multiple sclerosis (MS) treatments toward a diversified portfolio of newly launched growth products. Business segments include: * **Product Revenue (approx. 72% of total):** Includes the legacy MS franchise (Tecfidera, Vumerity, Avonex, Plegridy, Tysabri), spinal muscular atrophy (Spinraza), and rare disease products (Skyclarys, Qalsody, Zurzuvae). * **Anti-CD20 Therapeutic Programs (approx. 17% of total):** Primarily royalty revenue from Genentech for Ocrevus. * **Alzheimer's Collaboration Revenue (approx. 2% of total):** Biogen's 50% share of net profits from Leqembi, partnered with Eisai. * **Contract Manufacturing, Royalty, and Other (approx. 9% of total):** Manufacturing services provided to third parties. Key geographies are split between the US (approx. 55% of revenue) and Rest of World (approx. 45%). The business model is highly asset-heavy in research and development but relies heavily on strategic partnerships for commercialisation (e.g., Eisai for Alzheimer's, Sage Therapeutics for postpartum depression). Biogen's competitive position is currently challenged in MS by generic erosion but dominant in the emerging anti-amyloid Alzheimer's market (over 60% market share for Leqembi). Recent major events include the $7.3 billion acquisition of Reata Pharmaceuticals in 2023 to acquire Skyclarys, the discontinuation of the controversial Alzheimer's drug Aduhelm, and the ongoing "Fit for Growth" restructuring programme aimed at saving $1 billion gross by the end of 2025. ## Revenue Deep Dive ### Multiple Sclerosis (MS) Franchise * **Segment Name:** Product Revenue - Multiple Sclerosis (includes Tecfidera, Vumerity, Avonex, Plegridy, Tysabri). * **Revenue Driver Formula:** Total MS Patients x Market Share x Net Price per Patient. * **Historical Growth Rate:** Declining at 10% to 15% annually. * **Key Growth Levers and Headwinds:** Severe headwinds from generic competition for Tecfidera in the US and Europe. Vumerity provides slight offset but cannot replace lost volume. * **Pricing Dynamics:** Heavy gross-to-net discounting and rebate pressure from pharmacy benefit managers. * **Seasonality:** Q1 is typically the weakest quarter due to insurance deductible resets in the US. ### Spinal Muscular Atrophy (SMA) * **Segment Name:** Product Revenue - SPINRAZA. * **Revenue Driver Formula:** Global Patients on Therapy x Doses per Year x Net Price per Dose. * **Historical Growth Rate:** Declining low-to-mid single digits (down 2% in 2025, with a 15% drop in Q4 2025 due to ex-US shipment timing). * **Key Growth Levers and Headwinds:** Intense competition from oral (Evrysdi) and gene therapy (Zolgensma) alternatives. Growth lever is the potential approval of a high-dose regimen. ### Rare Disease & New Launches * **Segment Name:** Product Revenue - Rare Disease (SKYCLARYS, QALSODY, ZURZUVAE). * **Revenue Driver Formula:** New Patient Starts + Continuing Patients x Compliance Rate x Net Price. * **Historical Growth Rate:** Surging (Skyclarys grew 30% YoY in Q4 2025 to $133 million; Zurzuvae grew 187% YoY to $66 million). * **Key Growth Levers and Headwinds:** Skyclarys adoption in Friedreich's ataxia is the primary growth engine. Headwinds include Medicare discount dynamics and channel inventory fluctuations. ### Alzheimer's Collaboration * **Segment Name:** Alzheimer's Collaboration Revenue (LEQEMBI). * **Revenue Driver Formula:** (Global In-Market Sales x 50%) minus Biogen's share of commercialisation expenses. * **Historical Growth Rate:** Hyper-growth (In-market sales grew 140% in 2025 to over $500 million). * **Pricing Dynamics:** Fixed wholesale acquisition cost, but revenue recognition depends on the profit-sharing mechanics with Eisai. ### Anti-CD20 Therapeutic Programs * **Segment Name:** Revenue from Anti-CD20 Therapeutic Programs. * **Revenue Driver Formula:** Genentech Ocrevus Sales x Tiered Royalty Rate. * **Historical Growth Rate:** Mid-single digit growth. * **Pricing Dynamics:** Pure royalty stream with 100% flow-through to the bottom line. ## Cost Structure ### Variable Costs / COGS * **Line Items:** Cost of Sales, excluding amortisation of acquired intangible assets. * **Gross Margin Range:** Typically 75% to 80%. * **Key Input Costs:** Biologics manufacturing, raw materials, and royalties paid to third parties. * **Scaling Dynamics:** COGS scales linearly with product revenue, but the mix effect is powerful. Anti-CD20 revenue has zero COGS, while contract manufacturing has very high COGS. ### Operating Expenses * **R&D:** Typically 20% to 25% of revenue. Covers clinical trial execution, early-stage discovery, and regulatory filings. Biogen does not capitalise early-stage R&D. * **SG&A:** Typically 25% of revenue. Highly driven by sales force headcount and direct-to-consumer marketing for new launches like Leqembi and Skyclarys. * **Collaboration Profit Sharing:** A net expense line item (approx. $70 million in Q4 2025) reflecting payments to partners like Samsung Bioepis and Supernus Pharmaceuticals. * **Restructuring:** The "Fit for Growth" programme is generating $1 billion in gross savings ($800 million net of reinvestment) by the end of 2025, leading to significant one-time severance and facility closure charges. ### Margin Profile * **Operating Margin:** Non-GAAP operating margins typically range from 25% to 30%. * **Margin Trend:** Stabilising. The severe margin compression from the MS franchise decline is being offset by the "Fit for Growth" cost cuts and the scaling of high-margin royalties. ## Balance Sheet Structure * **Total Assets:** Approximately $25 billion. * **Key Asset Categories:** Cash and marketable securities ($4.2 billion at year-end 2025), Accounts Receivable, Inventory, PP&E, and a massive Intangibles/Goodwill balance. * **Goodwill & Intangibles:** Represents over 50% of total assets, driven heavily by the $7.3 billion Reata Pharmaceuticals acquisition in 2023. * **Working Capital Profile:** * **DSO:** 60 to 70 days. * **DIO:** 150 to 180 days (biologics require long manufacturing lead times). * **DPO:** 45 to 60 days. * **Net Working Capital:** Generally positive. The company does not use negative working capital to fund growth. * **PP&E:** Primarily large-scale biologics manufacturing facilities in North Carolina and Switzerland. Maintenance capex is relatively low. ## Capital Expenditure & Investment * **Capex as % of Revenue:** Very low, typically 1.5% to 2.0% ($154 million in 2025 on $9.9 billion in revenue). * **Maintenance vs. Growth:** The vast majority is maintenance capex for existing manufacturing sites. * **M&A Pattern:** Historically a mix of transformational (Reata for $7.3 billion) and bolt-on (HI-Bio, Alcyone Therapeutics for $85 million). * **Capitalised Software:** Immaterial to the overall financial profile. ## Debt & Capital Structure * **Total Debt:** $6.3 billion as of December 31, 2025. * **Net Debt:** $2.0 billion. * **Key Debt Instruments:** Primarily unsecured senior notes with staggered maturities. * **Interest Rate Profile:** Mostly fixed-rate bonds. * **Share Repurchase Programme:** Paused. The company did not repurchase shares in 2024 or 2025 to preserve capital for M&A and debt reduction, though $2.1 billion remains authorised. * **Dividend Policy:** Biogen does not pay a dividend. All capital is returned via share repurchases or reinvested in the pipeline. ## Cash Flow Characteristics * **OCF Conversion:** Very strong. Operating cash flow was $2.2 billion in 2025. * **Free Cash Flow Margin:** Approximately 21% ($2.1 billion FCF on $9.9 billion revenue in 2025). * **Major Non-Cash Items:** Depreciation, heavy amortisation of acquired intangibles, stock-based compensation, and acquired in-process R&D (IPR&D) charges. * **Working Capital Impact:** Modest use of cash as new product launches require inventory build-up. * **Cash Tax Rate:** Generally tracks the Non-GAAP effective tax rate of 17% to 18%. ## Sheet Structure 1. **Assumptions:** Hardcoded drivers for revenue growth, pricing, margins, tax rates, and working capital days. 2. **Revenue Build:** Detailed bottom-up forecast for MS (Tecfidera, Vumerity, Avonex, Plegridy, Tysabri), SMA (Spinraza), Rare Disease (Skyclarys, Qalsody, Zurzuvae), Anti-CD20, and Alzheimer's Collaboration (Leqembi). 3. **Income Statement:** GAAP and Non-GAAP views. Must explicitly break out "Collaboration profit sharing" and "Amortisation of acquired intangible assets" as separate line items. 4. **Balance Sheet:** Standard assets, liabilities, and equity. Must include a large line item for "Intangible assets, net". 5. **Cash Flow Statement:** Indirect method starting from Net Income. Must include add-backs for IPR&D and intangible amortisation. 6. **Debt Schedule:** Tranche-by-tranche breakdown of senior notes, calculating interest expense and tracking maturities. 7. **Working Capital:** Schedules for Accounts Receivable, Inventory, and Accounts Payable based on DSO, DIO, and DPO. 8. **DCF Valuation:** Unlevered free cash flow build, WACC calculation, and terminal value using the perpetuity growth method. ## Key Financial Relationships 1. `Total MS Revenue = Tecfidera Revenue + Vumerity Revenue + Avonex Revenue + Plegridy Revenue + Tysabri Revenue` 2. `Tecfidera Revenue = Prior Year Tecfidera Revenue * (1 + Tecfidera Growth Rate)` (Note: Growth rate will be negative). 3. `Alzheimer's Collaboration Revenue = (Global Leqembi In-Market Sales * 50%) - Biogen Commercialisation Expenses` 4. `Anti-CD20 Revenue = Projected Ocrevus Global Sales * Blended Royalty Rate` 5. `Total Product Revenue = Total MS Revenue + Spinraza Revenue + Rare Disease Revenue` 6. `Total Revenue = Total Product Revenue + Anti-CD20 Revenue + Alzheimer's Collaboration Revenue + Contract Manufacturing Revenue` 7. `Gross Profit = Total Revenue - Cost of Sales (excluding amortisation)` 8. `Non-GAAP Core OpEx = Non-GAAP R&D Expense + Non-GAAP SG&A Expense` 9. `Non-GAAP Operating Income = Total Revenue - Cost of Sales - Non-GAAP Core OpEx - Collaboration Profit Sharing` 10. `Free Cash Flow = Net Cash Provided by Operating Activities - Capital Expenditures` 11. `Net Debt = Total Debt - Cash and Cash Equivalents - Marketable Securities` ## Cross-Sheet Dependencies * The **Revenue Build** is the critical engine of the model. It feeds the top line of the **Income Statement**. * The **Income Statement** generates Net Income, which is the starting point for the **Cash Flow Statement**. * The **Cash Flow Statement** calculates the ending cash balance, which feeds the **Balance Sheet**. * The **Debt Schedule** uses cash flow available for debt service to pay down maturing notes, updating the debt balances on the **Balance Sheet**. * **Circularity Risk:** Interest expense on the **Income Statement** depends on the average debt balance from the **Debt Schedule**, which depends on cash flow, which depends on Net Income. A toggle switch must be included to break circular references. ## Sign Convention * **Income Statement:** Revenues are positive. All expenses (COGS, R&D, SG&A, Interest, Taxes) are negative. * **Balance Sheet:** Assets are positive. Liabilities and Equity are positive. * **Cash Flow Statement:** Cash inflows (e.g., Net Income, Depreciation add-back, increase in Accounts Payable) are positive. Cash outflows (e.g., Capital Expenditures, increase in Accounts Receivable, debt repayment) are negative. ## Things Most Likely to Go Wrong 1. **Leqembi Accounting:** Biogen does not book gross sales of Leqembi. It books its 50% share of net profits/losses under "Alzheimer's Collaboration Revenue". Treating this as gross product revenue will massively overstate the top line. 2. **Anti-CD20 Margin:** The Anti-CD20 revenue stream is a royalty. It has zero COGS. Applying a blended corporate gross margin to this line item will severely understate profitability. 3. **GAAP vs Non-GAAP EPS:** Biogen's GAAP earnings are heavily distorted by acquired IPR&D charges and intangible amortisation. The model must forecast Non-GAAP EPS to align with management guidance and consensus estimates. 4. **MS Franchise Erosion:** Underestimating the speed of generic erosion for Tecfidera in Europe will lead to overly optimistic revenue forecasts. Management expects MS revenue (excluding Vumerity) to decline by a mid-teens percentage in 2026. 5. **Fit for Growth Savings:** The model must reflect the $800 million in net OpEx savings by the end of 2025. Extrapolating historical SG&A as a percentage of revenue will overstate future costs. 6. **Contract Manufacturing Volatility:** This revenue line is lumpy and depends on campaign timing. It should not be modelled as a smooth growth curve. 7. **Share Count:** Biogen is not currently buying back stock. Holding the share count flat is the correct assumption until debt is further reduced. 8. **FX Headwinds:** Biogen has massive ex-US exposure. The model should ideally forecast on a constant-currency basis or explicitly flag FX impacts, as currency swings can alter revenue by 2% to 3% annually. ## Validation Checks 1. "Total Revenue for 2026 should decline by a mid-single-digit percentage compared to 2025 ($9.89 billion), per management guidance." 2. "Non-GAAP Diluted EPS for 2026 must fall between $15.25 and $16.25." 3. "MS product revenue (excluding Vumerity) should decline by approximately 15% in 2026." 4. "Non-GAAP effective tax rate must be between 17% and 18%." 5. "Free Cash Flow should be approximately $2.0 billion to $2.2 billion, consistent with 2025 actuals." 6. "Capital expenditures should not exceed 2% of total revenue." 7. "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every forecasted period." 8. "Gross margin and core OpEx should remain roughly consistent with 2025 levels in dollar terms." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | 2026 Total Revenue Growth | -5.0 | % | Mid-single digit decline per 2026 guidance | | 2026 MS Revenue Growth (ex-Vumerity) | -15.0 | % | Mid-teens decline per 2026 guidance | | 2026 Skyclarys Revenue | 600 | $ Millions | Annualising Q4 2025 run-rate ($133M) plus continued 30% patient growth | | 2026 Leqembi In-Market Sales | 800 | $ Millions | Continued ramp from 2025 base of >$500M | | Gross Margin | 76.0 | % | Consistent with historical averages and 2026 guidance | | Non-GAAP R&D as % of Revenue | 22.0 | % | Reflects reinvestment in pipeline offset by Fit for Growth savings | | Non-GAAP SG&A as % of Revenue | 24.0 | % | Reflects launch costs for new products offset by Fit for Growth savings | | Non-GAAP Effective Tax Rate | 17.5 | % | Midpoint of 2026 guidance (17% - 18%) | | Capital Expenditures | 150 | $ Millions | Flat to 2025 actuals ($154M) | | Diluted Shares Outstanding | 147 | Millions | Flat to Q4 2025 actuals; no buybacks assumed | | DSO (Days Sales Outstanding) | 65 | Days | Based on historical receivables turnover | | DIO (Days Inventory Outstanding) | 165 | Days | Based on historical inventory turnover for biologics | | WACC (Discount Rate) | 8.5 | % | Standard cost of capital for large-cap commercial biotech | | Terminal Growth Rate | 1.0 | % | Conservative long-term growth assumption given patent cliffs | ## Data Sources & Benchmarks * **Filings:** SEC EDGAR (Biogen 10-K, 10-Q, 8-K), Biogen Investor Relations website for quarterly earnings slides and press releases. * **Key Peers:** Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN). * **Industry Data:** IQVIA for prescription volume data (critical for tracking Leqembi and Skyclarys weekly scripts). * **Consensus Estimates:** Bloomberg or FactSet for Wall Street consensus on pipeline probability-of-success and peak sales estimates. ## Sources * Biogen Q4 and Full Year 2025 Earnings Press Release (February 6, 2026) * Biogen Q4 2025 Earnings Presentation Slides (February 6, 2026) * Biogen 2025 Form 10-K * Biogen Q3 2025 Earnings Press Release (October 30, 2025) * Biogen Q4 and Full Year 2024 Earnings Press Release (February 12, 2025) --- ## Frequently asked questions ### What is Biogen's primary business focus? Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering therapies for neurological, immunological, and rare diseases. The company is strategically shifting from its historical reliance on multiple sclerosis treatments towards a new portfolio of growth products. ### How does Biogen generate its revenue? Biogen generates revenue primarily from product sales, including its legacy MS franchise and new rare disease products, which constitute about 72% of its total revenue. Additional revenue streams include royalties from Anti-CD20 Therapeutic Programs, profits from Alzheimer's collaboration, and contract manufacturing services. ### What is the projected revenue growth rate for Biogen in the financial model? The financial model for Biogen assumes a revenue growth rate of approximately -9.06%. This reflects the company's strategic pivot and the structural decline of its legacy multiple sclerosis franchise. ### What is Biogen's typical capital expenditure as a percentage of revenue? Biogen's capital expenditure as a percentage of revenue is very low, typically ranging from 1.5% to 2.0%. The financial model uses a Capex_Pct_Revenue assumption of approximately 2.85%. ### What is the main purpose of the Biogen financial model? The Biogen financial model aims to evaluate whether the company's rapidly scaling growth products can generate sufficient cash flow to offset the decline of its legacy multiple sclerosis franchise. Ultimately, it assesses the company's equity valuation and its capacity for future pipeline-expanding acquisitions. ### Can I download an Excel financial model for Biogen? Yes, a downloadable Excel financial model is available for Biogen. This general corporate model provides a forecast horizon from FY2026 to FY2030. [Interactive forecast calculator](https://finamodel.com/companies/biogen/forecast)